DrugDashboards

Clobazam

clobazam · CLOBAZAM 2.5 mg/mL · Suspension · Oral · Precision Dose, Inc.

NDC 68094-0074-58 · 50 BAG in 1 CASE / 1 SYRINGE, PLASTIC in 1 BAG / 4 mL in 1 SYRINGE, PLASTIC · ANDA · View full market →

The short version

11 companies supply this market — deep enough that no single failure threatens the supply.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 67386-0313-21) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$12.86per unit
middle half $12.86$12.86 · 2 plans · Apr 1, 2026
Est. net of rebates
≈ $12.86
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
0%of plans cover it
tier 1 · prior auth 100% · step therapy 0% · qty limit 100%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for clobazam (other) in the next 90 days

sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Regulatory

Application
ANDA210039
TE code
AB
Approval date
Oct 22, 2018
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of clobazam (Suspension)

LabelerStrengthFirst seenLast seen
Sun Pharmaceutical Industries, Inc.CLOBAZAM 2.5 mg/mLJul 16, 2026Sep 3, 2026
Amneal Pharmaceuticals NY LLCCLOBAZAM 2.5 mg/mLJul 15, 2026Sep 2, 2026
Ascend Laboratories, LLCCLOBAZAM 2.5 mg/mLJul 15, 2026Sep 2, 2026
Aurobindo Pharma LimitedCLOBAZAM 2.5 mg/mLJul 15, 2026Sep 2, 2026
Bionpharma Inc.CLOBAZAM 2.5 mg/mLJul 15, 2026Sep 2, 2026
Bryant Ranch PrepackCLOBAZAM 2.5 mg/mLJul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.CLOBAZAM 2.5 mg/mLJul 15, 2026Sep 2, 2026
Chartwell RX, LLCCLOBAZAM 2.5 mg/mLJul 15, 2026Sep 2, 2026
Lundbeck Pharmaceuticals LLCCLOBAZAM 2.5 mg/mLJul 15, 2026Sep 2, 2026
NorthStar RxLLCCLOBAZAM 2.5 mg/mLJul 15, 2026Sep 2, 2026
Precision Dose, Inc.CLOBAZAM 2.5 mg/mLJul 15, 2026Sep 2, 2026
Taro Pharmaceuticals U.S.A., Inc.CLOBAZAM 2.5 mg/mLJul 15, 2026Jul 15, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Clobazam — NDC 68094-0074-58," retrieved September 3, 2026, https://drugdashboards.com/drug/68094007458.

Free to cite with attribution — see how the data is put together.